Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Health and Quality of Life Outcomes
Published in: Health and Quality of Life Outcomes 1/2005

Open Access 01-12-2005 | Research

Minimal Important Difference (MID) of the Dermatology Life Quality Index (DLQI): Results from patients with chronic idiopathic urticaria

Authors: Richard Shikiar, Gale Harding, Michael Leahy, Richard D Lennox

Published in: Health and Quality of Life Outcomes | Issue 1/2005

Login to get access

Abstract

Background

The Dermatology Quality Life Index (DLQI) has seen widespread use as a health-related quality of life measure for a variety of dermatological diseases. The purpose of this study was to estimate the minimal important difference (MID) on the DLQI for patients with chronic idiopathic urticaria (CIU).

Methods

Data from 2 Phase III clinical trials of patients (N = 476 for Study A; N = 468 for Study B) with CIU were analyzed separately to estimate the MID for the DLQI for these populations. Both distributional based and anchor based approaches were used for deriving estimates. The anchor based approach relied upon patient self assessments of pruritus severity; the distributional based approaches relied upon estimating the standard error of measurement, as well as one-half the standard deviation of the DLQI from each study.

Results

The distributional approaches resulted in estimates of MID ranging from 2.24 to 3.10 for the two studies. The anchor based approach resulted in estimates of 3.21 and 2.97 for the two studies.

Conclusion

An MID for the DLQI in the range of 2.24 to 3.10 is recommended in interpreting results for patients with CIU.
Literature
1.
Ryan TJ: Disability in dermatology. Br J Hosp Med 1991, 46: 33–36.PubMed
2.
Jowett S, Ryan T: Skin disease and handicap: an analysis of the impact of skin conditions. Soc Sci Med 1985, 20: 425–429. 10.1016/0277-9536(85)90021-8PubMedCrossRef
3.
Ginsburg IH, Link BG: Feeling of stigmatization in patients with psoriasis. J Am Acad Dermatol 1989, 20: 53–63.PubMedCrossRef
4.
Touw CR, Hakkaart-Van Roijen L, Verboom P, Paul C, Rutten FF, Finlay AY: Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol 2001, 144: 967–972. 10.1046/j.1365-2133.2001.04183.xPubMedCrossRef
5.
Nelson HS, Reynolds R, Mason J: Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2000,84(5):517–522.PubMedCrossRef
6.
Finn AF Jr, Kaplan AP, Fretwell R, Qu R, Long J: A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 1999, 104: 1071–1078.PubMedCrossRef
7.
Grosshans E, Marks R, Mascaro JM, Torras H, Meynadier J, Alirezai M, Finlay AY, Soto P, Poncet M, Verschoore M, Clucas A: Evaluation of clinical efficacy and safety of adapalene 0.1% gel versus tretinoin 0.025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life. Br J Dermatol 1998,139(Suppl 52):26–33. 10.1046/j.1365-2133.1998.1390s2026.xPubMedCrossRef
8.
Finlay AY, Coles EC: The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995, 132: 236–244.PubMedCrossRef
9.
Finlay AY, Khan GK: Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994, 19: 210–216.PubMedCrossRef
10.
Sloan JA, Symonds T, Vargas-Chanes D, Friedly B: Practical guidelines for assessing the clinical significance of heath related quality of life changes within clinical trials. Drug Inf J 2003, 37: 23–31.
11.
Juniper EF, Guyatt GH, Willan A, Griffith LE: Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994, 47: 81–87. 10.1016/0895-4356(94)90036-1PubMedCrossRef
12.
Juniper EF: The value of quality of life in asthma. Eur Respir Rev 1997, 7: 333–337.
13.
Juniper EF: Quality of life questionnaires: does statistically significant = clinically important? J Allergy Clin Immunol 1998, 102: 16–17.PubMedCrossRef
14.
Wyrwich KW, Nienaber NA, Tierney WM, Wolinsky FD: Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care 1999, 37: 469–478. 10.1097/00005650-199905000-00006PubMedCrossRef
15.
Wyrwich KW, Tierney WM, Wolinsky FD: Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 1999, 52: 861–873. 10.1016/S0895-4356(99)00071-2PubMedCrossRef
16.
Norman GR, Sloan JA, Wyrwich KW: Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003, 41: 582–592. 10.1097/00005650-200305000-00004PubMed
17.
McHorney CA, Tarlov AR: Individual-patient monitoring in clinical practice: are available health status surveys adequate? Qual Life Res 1995, 4: 293–307. 10.1007/BF01593882PubMedCrossRef
18.
Cella D, Hahn EA, Dineen K: Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res 2002, 11: 207–221. 10.1023/A:1015276414526PubMedCrossRef
19.
Guyatt GH, Jaeschke RJ: Reassessing quality-of-life instruments in the evaluation of new drugs. Pharmacoeconomics 1997, 12: 621–626.PubMedCrossRef
20.
Ware JE, Snow KK, Kosinski MK, Gandek B: SF-36 Health Survey: Manual and Interpretation Guide. Boston: The Health Institute, New England Medical Center; 1993.
21.
Shikiar R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA: Validity and reliability of patient reported outcomes used in Psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes 2003, 1: 53. 10.1186/1477-7525-1-53PubMedCentralPubMedCrossRef
22.
Khilji FA, Gonzalez M, Finlay AY: Clinical meaning of change in Dermatology Life Quality Index scores. Br J Dermatol 2002,147(Suppl 2):50.
Metadata
Title
Minimal Important Difference (MID) of the Dermatology Life Quality Index (DLQI): Results from patients with chronic idiopathic urticaria
Authors
Richard Shikiar
Gale Harding
Michael Leahy
Richard D Lennox
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2005
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/1477-7525-3-36

Other articles of this Issue 1/2005

Health and Quality of Life Outcomes 1/2005 Go to the issue

Research

The International Classification of Functioning as an explanatory model of health after distal radius fracture: A cohort study

Research

Quality of life in children newly diagnosed with cancer and their mothers

Research

Factor structure of the Hospital Anxiety and Depression Scale (HADS) in German coronary heart disease patients

Research

Health related quality of life in sickle cell patients: The PiSCES project

Research

Can the concepts of depression and quality of life be integrated using a time perspective?

Research

The measurement of response shift in patients with advanced prostate cancer and their partners